The 2018 aha/acc/aacvpr/ aapa/abc/acpm/ada/ags/ apha/aspc/nla/pcna* guidelines on the management of blood cholesterol in diabetes

Ronald B. Goldberg*, Neil J. Stone, Scott M. Grundy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


The American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines recently published its 2018 recommendations on management of LDL cholesterol (LDL-C) in people with diabetes. For primary prevention, moderate-intensity statin therapy is recommended for those aged 40–75 years, with a preference for high-intensity statin treatment for older subjects and for those with higher estimated risk or risk-enhancing factors following a patient-clinician discussion. Statin therapy may be reasonable in adults <40 years or >75 years of age where there is less evidence for benefit. For people with diabetes and established atherosclerotic cardiovascular disease, high-intensity statin therapy is recommen-ded. The majority of these subjects have very high risk, and an LDL-C goal of <70 mg/ dL is recommended. If this target is not achieved, ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor may be added.

Original languageEnglish (US)
Pages (from-to)1673-1678
Number of pages6
JournalDiabetes care
Issue number8
StatePublished - Aug 2020

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing


Dive into the research topics of 'The 2018 aha/acc/aacvpr/ aapa/abc/acpm/ada/ags/ apha/aspc/nla/pcna<sup>*</sup> guidelines on the management of blood cholesterol in diabetes'. Together they form a unique fingerprint.

Cite this